波兰药品产业生物科技创新：2009年

波兰药品产业生物科技创新：2009年 是由出版商PMR在2009年08月所出版的。 这份英文市场调查报告书包含85 pages 价格从美金2612起跳。

简介

本报告书内容包括：波兰药品产业生物科技的市场价値、在国内及国际市场中活跃的波兰生物科技企业、利基市场、针对波兰的投资动向、法规限制动向等。内容纲要摘记如下：

调查方法

实施概要

波兰药品生物科技市场概要

• 波兰生物科技市场的主要事件及动向
• 波兰生物科技市场的主要特色
• 市场价値：2003年至2011年

波兰生物科技企业

• 针对波兰生物科技市场的海外投资
• 波兰生物科技企业数量及分类
• 最大型企业概要
• 与药品产业相关的生物科技企业

波兰药品产业的生物科技创新

• 干细胞疗法
• 利用siRNA的创新生物药品
• 修饰单株抗体治疗
• 组织工程及再生医疗
• 治疗皮肤癌、肾脏癌的创新疫苗
• 生物药品开发的创新平台
• 科学与产业的接点创新
• 有助于新药开发的生物科技创新

波兰生物科技发展的影响因素

• 人才
• 针对医疗生物科技的意见
• 法规限制环境
  • 主要规范
  • 针对基因重组生物的因应对策
  • 专利法
  • 支持创新的法规
  • 波兰生物科技市场的品质标准
• 支持技术创新及技术移转的行动方案
• 高风险资金的接触度

图

表

PMR介绍

PMR的联络对象

目录

Abstract

Description:

Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sector in recent years. From an operational point of view, the report profiles the major players active on the Polish market, as well as the legislative setting they face. A directory of the 20 largest biopharmaceutical companies and developmental forecasts up to 2011 is included.

• the value of biotechnology market Polish pharmaceutical industry
• details on Polish biotech firms investing in development of domestic and international market
• data on niche biotech market segments in Poland
• key players on the market profiles
• undergoing investments in Poland
• legislation briefing regarding biotechnology market in Poland

Our reports are prepared using PMR' s MarketInsight Methodology. PMR MarketInsight is a methodology developed by PMR which assists in the complex preparation of industry reports. It defines the ways in which data should be collected for such reports and outlines the methods to be used in analysing the information collected in order to obtain a true picture of the market in question. It also contains special procedures to follow in the case of incomplete market.

PMR MarketInsight precisely defines report content and structure. Industry reports prepared using PMR MarketInsight are based on information from a variety of available statistical, industry (specialist press, the internet), general and official sources as well as information from PMR?s own database and primary research independently carried out by PMR. The sources we use are individually tailored to each project.

PMR MarketInsight is the result of over 13 years of experience in conducting industry analysis on Central and Eastern European markets.

Table of Contents

I. Report methodology

II. Executive summary

III. Overview of the Polish market of pharmaceutical biotechnology

• Key events and trends in the biotechnology sector in Poland
  • Key trends and events in 2007-2009
  • Events and trends anticipated for 2009-2011
• Key characteristics of the Polish market of biotechnology in pharmaceutics
• Value of the Polish market of pharmaceutical biotechnology 2003-2011

IV. Biotech firms in Poland

• Foreign investment on the Polish pharmaceutical biotechnology market
• Number and classification of Polish biotech firms
• Overview of the largest biotech firms on the Polish pharmaceutical market
• Biotech companies connected with the pharmaceutical industry

V. Selected biotechnological innovations of the Polish pharmaceutical industry

• Stem cell therapy: Celther
• siRNA-based innovative biotech drug: Celon Pharna
• Modified monoclonal antibody therapy: Mabion
• Tissue engineering and regenerative medicine: Euroimplant
• Innovative vaccines against skin and kidney cancer: Biocontract
• Innovative platform for the development of biotech drugs: Adamed
• Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute
• Biotech innovations leading to the development of new pharmaceutical substances
  • Advanced molecular diagnostics for clinical trials: Read-Gene
  • New technologies for the development of biotech drugs: BioCentrum
  • Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals
  • BioIT as support for the development of innovative drugs: Selvita

VI. Factors material to the development of biotechnology in Poland

• Human resources
• Opinions about biotechnology in medicine
• Legislative environment
  • Key regulations
  • Act on genetically modified organisms
  • Patent law
  • Legislative support for innovation
  • Quality standards in the Polish biotech sector
• Initiatives supporting the development of innovation and technology transfer
  • Science & technology and industrial parks
    • General overview
    • Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland
  • Clusters
  • EU funding for the development of biotechnology innovations
  • Access to higher risk capital

VII. List of graphs

VIII. List of tables

IX. About PMR

X. Contact PMR

List of graphs

• 1. Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12
• 2. Bioton' s revenues (PLN m) and revenue y-o-y change, 2003-2008
• 3. Bioton' s net financial result (PLN m), 2003-2008
• 4. Bioton' s revenues and net financial result (PLN m), Q1 2008 and Q1 2009
• 5. IBSS Biomed' s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007
• 6. IBSS Biomed' s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007
• 7. Biomed Lublin' s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008
• 8. Biomed Lublin' s net financial result (PLN m) in Poland, 1998-2008
• 9. Polfa Tarchomin' s sales value structure, 2007
• 10. Polfa Tarchomin' s domestic sales value structure, 2008
• 11. Polfa Tarchomin' s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009
• 12. Polfa Tarchomin' s net financial result (PLN m), 1998-Q1 2009
• 13. Percentage shareholdings in Mabion of Poland, 2009
• 14. Euroimplant' s net financial result (PLN' 000) in Poland, 2007-2008
• 15. Biocontract' s financial results (PLN m) in Poland, 2007
• 16. Adamed' s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008
• 17. Adamed' s net financial result (PLN m), 1999-2008
• 18. Read-Gene' s net financial result (PLN' 000) in Poland, 2005-2009
• 19. Forecast for Read-Gene' s revenue and net profit structure in Poland, 2009
• 20. BioCentrum' s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007
• 21. BioCentrum' s net profit (PLN' 000) and net profit y-o-y change in Poland, 2004-2007
• 22. Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008
• 23. Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008
• 24. Assessment of results of use of modern biotechnological methods in Poland
• 25. Poles' opinion on use of biotechnology to produce new drugs and vaccines
• 26. Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”
• 27. Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009
• 28. Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009

List of tables

• 1. Structure of Bioton Capital Group, 2008
• 2. The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009
• 3. Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009
• 4. Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009

相关商品

Email Alert(Email 通知) - 最新市场调查报告书

GII 将每天定期更新最新市场调查报书信息，选择您有兴趣的市场分类，我们将用Email的方式让您收到最新讯息!